Starting materials are vital to the reliable supply of high-quality medicines. As critical building blocks of active pharmaceutical ingredients (APIs), these materials influence everything from product purity to supply chain security. Yet, years of focus on upfront costs over systemic risks have concentrated suppliers geographically and reduced supply chain control, highlighting the need for a strategy that supports control, quality, and cost efficiency.
This white paper explores how an integrated approach to starting material production builds supply chain resilience, streamlines logistics, improves transparency, and enables faster problem-solving.
